Oncolytics Biotech (US:ONCY) Globenewswire·2026-01-12 14:00Core Insights - The combination of pelareorep and atezolizumab has shown a nearly tripled objective response rate (ORR) compared to historical benchmarks, achieving an ORR of approximately 29% in a heavily pretreated population of third-line metastatic squamous cell anal carcinoma (SCAC) patients [1][3][5] - The median duration of response (DOR) for this combination therapy is approximately 17 months, indicating significant clinical benefit in a setting with no FDA-approved therapies [1][3][5] Clinical Data Summary - In the updated GOBLET Cohort 4, four out of 14 evaluable patients achieved objective responses, including two complete responses and two partial responses [3][4] - Historical studies in third-line SCAC typically report an ORR of around 10% or less, highlighting the potential of pelareorep plus atezolizumab in addressing unmet medical needs [4][5] Development Strategy - Oncolytics plans to pursue a registration study based on the promising data from GOBLET Cohort 4, aiming for accelerated approval from the FDA [7] - The company has received initial positive feedback from key opinion leaders (KOLs) and the FDA, with a Type C meeting scheduled for Q1 2026 to discuss the development plan [7]